FDA approves QALSODY™ (tofersen) as the first treatment targeting a genetic cause of ALS ...Middle East

Accelerated approval marks a scientific advancement in treatment of superoxide dismutase 1 (SOD1)-amyotrophic lateral sclerosis (ALS) Approval based on reduction of neurofilament, a biomarker associated with neuronal damage in ALS QALSODY joins SPINRAZA® as Ionis-discovered medicine...

Hence then, the article about fda approves qalsody tofersen as the first treatment targeting a genetic cause of als was published today ( Wednesday 26/04/2023 - 02:20 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( FDA approves QALSODY™ (tofersen) as the first treatment targeting a genetic cause of ALS )

Also on site :

• Union boss ‘held up Communist flag alongside people singing pro-Russia chants in occupied Ukraine’
• Large house fire near Buckeye Lake kills one, critically injures second victim
• Regained momentum sets Yemen government’s eyes on Houthis in the north